Heron Posts $35.3M Q3 Revenue, Down 7.8%, With No 2026 Outlook
HRTX sits 55% above its 52-week low of $0.261.
Summary
Heron reported Q3 2026 net revenue of $35.3 million, down 7.8% year-over-year, and held $23.4 million in cash. The company is giving no financial guidance after withdrawing its full-year 2026 outlook in August. Commercial SUSTOL sales stopped September 30, 2026, removing a product from the revenue base without a quantified impact in the release. The results land the same morning Heron disclosed an agreement to sell substantially all of its assets to CorMedix for $145 million in cash plus 14,583,333 CorMedix shares, so the quarter's numbers matter mainly as a read on the business being handed over rather than as a standalone operating story.
At the time of this announcement, HRTX was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.6M. The 52-week trading range was $0.26 to $1.58. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.